19 records found.
Dec 14, 2018
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
Dec 04, 2018
Late-Breaking Clinical Trials Present Clinic-Ready Advances for Non-Malignant Diseases
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Sep 08, 2018
Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing
Aug 26, 2018
Researcher finds new blood clot prevention strategy
Jun 14, 2018
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
May 24, 2018
AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Feb 16, 2018
Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.
Jan 16, 2018
FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin
Dec 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Nov 01, 2017
ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio
Oct 30, 2017
FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Aug 28, 2017
In Canadian-Led Phase III Clinical Study, Xarelto® when Combined with ASA Significantly Lowered the Combined Risk of Stroke, Cardiovascular Death, and Heart Attack in Patients with Chronic Coronary or Peripheral Artery Disease by 24%
Aug 27, 2017
XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Aug 21, 2017
New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study
Jul 25, 2017
Report: More than 15,000 Adverse Events Linked to Xarelto in 2016
Jun 28, 2017
U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)